Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: Results from the CA209-003 study

Journal of Clinical Oncology

Volumn 36, Issue 17, 2018, Pages 1675-1684

  Gettinger, Scott ^a   Horn, Leora ^b   Jackman, David ^d   Spigel, David ^c   Antonia, Scott ^a   Hellmann, Matthew ^f   Powderly, John ^g   Heist, Rebecca ^e   Sequist, Lecia V ^e   Smith, David C ^h   Leming, Philip ⁱ   Geese, William J ^j   Yoon, Dennis ^j   Li, Ang ^j   Brahmer, Julie ^k  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g Carolina BioOncology Institute   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ CHRIST HOSPITAL   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTHRITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERSENSITIVITY; INFUSION RELATED REACTION; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SEPSIS; SKIN DISEASE; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; LUNG TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIVOLUMAB; SURVIVAL RATE;

EID: 85046686545     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2017.77.0412     Document Type: Article

References (23)

1. Brahmer J, Reckamp KL, Baas P, et al: Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 373: 123-135, 2015
2. Borghaei H, Paz-Ares L, Horn L, et al: Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373: 1627-1639, 2015
3. Reck M, Taylor F, Penrod JR, et al: Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: Results from the CheckMate 017 study. J Thorac Oncol 13:194-204, 2018
4. Gralla RJ, Spigel D, Bennett B, et al: Lung cancer symptom scale as a marker of treatment
5. benefit with nivolumab vs docetaxel in patients with advanced non-squamous NSCLC from CheckMate 057. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 3-7, 2016
6. Reck M, Brahmer J, Bennett B, et al: Overall health status in patients with advanced nonsquamous NSCLC treated with nivolumab or docetaxel in CheckMate 057. Presented at the European Society for Medical Oncology 41st Congress, Copenhagen, Denmark, October 7-11, 2015
7. Bristol-Myers Squibb: OPDIVO [package insert]. 2018. https://packageinserts.bms.com/pi/pi_opdivo.pdf
8. Bristol-Myers Squibb: Annex I: Summary of product characteristics [OPDIVO]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/003985/WC500189765.pdf
9. Herbst RS, Baas P, Kim DW, et al: Pem-brolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016
10. Rittmeyer A, Barlesi F, Waterkamp D, et al: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255-265, 2017
11. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
12. Gettinger SN, Horn L, Gandhi L, et al: Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004-2012, 2015
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
14. Wolchok JD, Hoos A, O’Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
15. National Cancer Institute Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (version 3.0). 2009. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ctcaev3.pdf
16. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
17. Vokes EE, Ready N, Felip E, et al: Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 10.1093/annonc/ mdy041 [epub ahead of print on February 2, 2018]
18. Leighl NB, Hellmann MD, Hui R, et al: KEYNOTE-001: 3-year survival for patients with advanced NSCLC treated with pembrolizumab. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, June 2-6, 2017
19. Park K, Lewanski C, Gadgeel S, et al: 3-year survival and duration of response in randomized phase II study of atezolizumab vs docetaxel in 2L/3L NSCLC (POPLAR). Presented at the IASLC 18th World Conference on Lung Cancer, Yokohama, Japan, October 15-18, 2017
20. William WN, Jr., Lin HY, Lee JJ, et al: Revisiting stage IIIB and IV non-small cell lung cancer: Analysis of the surveillance, epidemiology, and end results data. Chest 136:701-709, 2009
21. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7-30, 2016
22. Horn L, Spigel DR, Vokes EE, et al: Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35:3924-3933, 2017
23. Spigel DR, McCleod M, Hussein MA, et al: Randomized results of continuous vs 1-year fixed-duration nivolumab in patients with advanced non-small cell lung cancer. Presented at the European Society for Medical Oncology 2017 Congress, Madrid, Spain, September 8-12, 2017